Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleChemotherapy, Antibiotics, and Gene Therapy

Proteasome Regulator Marizomib (NPI-0052) Exhibits Prolonged Inhibition, Attenuated Efflux, and Greater Cytotoxicity than Its Reversible Analogs

Amanda Obaidat, Jeffrey Weiss, Brett Wahlgren, Rama R. Manam, Venkat R. Macherla, Katherine McArthur, Ta-Hsiang Chao, Michael A. Palladino, G. Kenneth Lloyd, Barbara C. Potts, Salvatore J. Enna, Saskia T. C. Neuteboom and Bruno Hagenbuch
Journal of Pharmacology and Experimental Therapeutics May 2011, 337 (2) 479-486; DOI: https://doi.org/10.1124/jpet.110.177824
Amanda Obaidat
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Weiss
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brett Wahlgren
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rama R. Manam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Venkat R. Macherla
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine McArthur
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ta-Hsiang Chao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael A. Palladino
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Kenneth Lloyd
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara C. Potts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salvatore J. Enna
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saskia T. C. Neuteboom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno Hagenbuch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The present study was undertaken to compare the cellular transport characteristics of [3H]NPI-0052 (1R,4R,5S)-4-(2-chloroethyl)-1-((S)-((S)-cyclohex-2-enyl)(hydroxy)methyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione (marizomib; salinosporamide A) and [3H]NPI-0047 (1R,4R, 5S)-1-((S)-((S)-cyclohex-2-enyl)(hydroxy)methyl)-4-ethyl-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione in RPMI 8226 multiple myeloma and PC-3 prostate adenocarcinoma cells to determine whether these properties explain differences in the cytotoxic potencies of these chemical analogs. The results indicate that marizomib, which possesses a chemical-leaving group, is more cytotoxic to both cell lines and inhibits proteasome activity more completely at lower concentrations than NPI-0047, a nonleaving-group analog. Moreover, it was found that both compounds accumulate in these cells by simple diffusion and the same carrier-mediated transport system. Although the rate of uptake is similar, the cellular efflux, which does not seem to be mediated by a major ATP-binding cassette (ABC)-efflux transporter, is more rapid for NPI-0047 than for marizomib. Experiments revealed that the irreversible binding of marizomib to the proteasome is responsible for its slower efflux, longer duration of action, and greater cytotoxicity compared with NPI-0047. The discovery that major ABC transporters of the multidrug resistance-associated protein family do not seem to be involved in the accumulation or removal of these agents suggests they may not be affected by multidrug resistance mechanisms during prolonged administration.

Footnotes

  • This work was supported by the National Institutes of Health National Institute of General Medical Sciences [Grant R01-GM077336]; the National Institutes of Health National Center for Research Resources [Grant P20-RR021940]; and Nereus Pharmaceuticals, Inc., San Diego, CA. A.O. was supported in part by the National Institutes of Health National Institute of Environmental Health Sciences [Grant T32-ES07079].

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

    doi:10.1124/jpet.110.177824.

  • ABBREVIATIONS:

    CP
    core particle
    ABC
    ATP-binding cassette
    CT-L
    chymotrypsin-like
    FBS
    fetal bovine serum
    LG
    leaving group
    NLG
    nonleaving group
    MM
    multiple myeloma
    PBS
    phosphate-buffered saline
    DMSO
    dimethyl sulfoxide
    HPLC
    high-performance liquid chromatography
    MRP
    multidrug resistance protein
    NPI-0052
    (1R,4R,5S)-4-(2-chloroethyl)-1-((S)-((S)-cyclohex-2-enyl)(hydroxy)methyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
    NPI-0047
    (1R,4R,5S)-1-((S)-((S)-cyclohex-2-enyl)(hydroxy)methyl)-4-ethyl-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
    MK-571
    3-[[[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propanoic acid
    NPI-2063
    (1R,4R,5S)-1-((S)-((S)-cyclohex-2-enyl)(hydroxy)methyl)-4,5-dimethyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
    NPI-2080
    (1R,4R,5S)-1-((S)-((S)-cyclohex-2-enyl)(hydroxy)methyl)-5-methyl-4-propyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
    NPI-2150
    2-((1R,4R,5S)-1-((S)-((S)-cyclohex-2-enyl)(hydroxy)methyl)-5-methyl-3,7-dioxo-6-oxa-2-azabicyclo[3.2.0]heptan-4-yl)ethyl methanesulfonate
    NPI-2151
    2-((1R,4R,5S)-1-((S)-((S)-cyclohex-2-enyl)(hydroxy)methyl)-5-methyl-3,7-dioxo-6-oxa-2-azabicyclo[3.2.0]heptan-4-yl)ethyl benzenesulfonate
    NPI-2162
    (1S,4R,5S)-4-(2-chloroethyl)-1-((S)-cyclohex-2-enecarbonyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
    NPI-2146
    (1S,4R,5S)-1-((S)-cyclohex-2-enecarbonyl)-4-ethyl-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione.

  • Received December 6, 2010.
  • Accepted February 7, 2011.
  • Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 384 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 384, Issue 2
1 Feb 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Proteasome Regulator Marizomib (NPI-0052) Exhibits Prolonged Inhibition, Attenuated Efflux, and Greater Cytotoxicity than Its Reversible Analogs
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleChemotherapy, Antibiotics, and Gene Therapy

Proteasome Regulator Marizomib (NPI-0052) Exhibits Prolonged Inhibition, Attenuated Efflux, and Greater Cytotoxicity than Its Reversible Analogs

Amanda Obaidat, Jeffrey Weiss, Brett Wahlgren, Rama R. Manam, Venkat R. Macherla, Katherine McArthur, Ta-Hsiang Chao, Michael A. Palladino, G. Kenneth Lloyd, Barbara C. Potts, Salvatore J. Enna, Saskia T. C. Neuteboom and Bruno Hagenbuch
Journal of Pharmacology and Experimental Therapeutics May 1, 2011, 337 (2) 479-486; DOI: https://doi.org/10.1124/jpet.110.177824

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleChemotherapy, Antibiotics, and Gene Therapy

Proteasome Regulator Marizomib (NPI-0052) Exhibits Prolonged Inhibition, Attenuated Efflux, and Greater Cytotoxicity than Its Reversible Analogs

Amanda Obaidat, Jeffrey Weiss, Brett Wahlgren, Rama R. Manam, Venkat R. Macherla, Katherine McArthur, Ta-Hsiang Chao, Michael A. Palladino, G. Kenneth Lloyd, Barbara C. Potts, Salvatore J. Enna, Saskia T. C. Neuteboom and Bruno Hagenbuch
Journal of Pharmacology and Experimental Therapeutics May 1, 2011, 337 (2) 479-486; DOI: https://doi.org/10.1124/jpet.110.177824
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • miR-9-3p and -5p Mediate Drug Resistance by Targeting TOP2β
  • Ocular Palonosetron for Prevention of Nausea and Vomiting
  • PTP4A3 and ovarian cancer
Show more Chemotherapy, Antibiotics, and Gene Therapy

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics